Journal article
Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A
The New England journal of medicine, Vol.391(3), pp.235-246
07/18/2024
DOI: 10.1056/NEJMoa2312611
PMID: 39018533
Abstract
Background: Once-weekly efanesoctocog alfa provides high sustained factor VIII activity with superior bleeding prevention as compared with prestudy factor VIII prophylaxis in previously treated patients 12 years of age or older with severe hemophilia A. Data on outcomes of efanesoctocog alfa treatment in children younger than 12 years of age with severe hemophilia A are limited.
Methods: We conducted a phase 3, open-label study involving previously treated patients younger than 12 years of age with severe hemophilia A. Patients received prophylaxis with once-weekly efanesoctocog alfa (50 IU per kilogram of body weight) for 52 weeks. The primary end point was the occurrence of factor VIII inhibitors (neutralizing antibodies against factor VIII). Secondary end points included annualized rates of treated bleeding episodes, bleeding treatment, safety, and pharmacokinetics.
Results: A total of 74 male patients were enrolled (38 with an age of <6 years and 36 with an age of 6 to <12 years). No factor VIII inhibitors developed. Most adverse events were nonserious. No serious adverse events that were assessed by the investigator as being related to efanesoctocog alfa were reported. In the 73 patients treated according to the protocol, the median and model-based mean annualized bleeding rates were 0.00 (interquartile range, 0.00 to 1.02) and 0.61 (95% confidence interval, 0.42 to 0.90), respectively. A total of 47 patients (64%) had no treated bleeding episodes, 65 (88%) had no spontaneous bleeding episodes, and 61 (82%) had no episodes of bleeding into joints. A total of 41 of 43 bleeding episodes (95%) resolved with one injection of efanesoctocog alfa. Mean factor VIII activity at steady state was more than 40 IU per deciliter for 3 days and more than 10 IU per deciliter for almost 7 days after dose administration. The geometric mean terminal half-life was 40.0 hours.
Conclusions: In children with severe hemophilia A, once-weekly prophylaxis with efanesoctocog alfa provided high sustained factor VIII activity in the normal to near-normal range (>40 IU per deciliter) for 3 days and more than 10 IU per deciliter for almost 7 days after administration, leading to effective bleeding prevention. Efanesoctocog alfa was associated with mainly nonserious adverse events. (Funded by Sanofi and Sobi; XTEND-Kids ClinicalTrials.gov number, NCT04759131.).
Details
- Title: Subtitle
- Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A
- Creators
- Lynn MalecFlora PeyvandiAnthony K.C. ChanChristoph KönigsBulent ZulfikarHuixing YuanMindy SimpsonMaria Teresa Álvarez RománManuel CarcaoJanice M. StaberAmy L. DunnSheng-Chieh ChouRoseline d’OironManuela AlbisettiMarek DemissieElena SantagostinoAbhimanyu YarramaneniNancy WongLydia Abad-FranchSriya GunawardenaKarin Fijnvandraat
- Resource Type
- Journal article
- Publication Details
- The New England journal of medicine, Vol.391(3), pp.235-246
- Publisher
- Massachusetts Medical Society
- DOI
- 10.1056/NEJMoa2312611
- PMID
- 39018533
- ISSN
- 0028-4793
- eISSN
- 1533-4406
- Language
- English
- Date published
- 07/18/2024
- Academic Unit
- Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Hematology/Oncology
- Record Identifier
- 9984658256302771
Metrics
3 Record Views